Buffett, Starboard Among the Elite Investors to Disclose New Moves

Page 3 of 3

According to a separate Form 4 filing, Jeremy Green’s Redmile Group purchased 925,000 shares of Array Biopharma Inc. (NASDAQ:ARRY) at prices that fell between $3.46 per share and $3.85 per share. Following the recent purchases, Redmile Group holds an ownership stake of 18.78 million shares in the biopharmaceutical company. Array Biopharma Inc. (NASDAQ:ARRY) focuses on discovering and developing targeted small molecule drugs to treat patients afflicted with cancer. The company is currently conducting three pivotal trials of binimetinib and/or encorafenib: COLUMBUS, which studies encorafenib in combination with binimetinib in BRAF-mutant melanoma patients; NEMO, which examines binimetinib in NRAS-mutant melanoma patients; and MILO, which studies binimetinib in low-grade serous ovarian cancer patients. In December, the company reported top-line results from its NEMO trial of binimetinib in patients with NRAS-mutant melanoma.

The number of hedge funds from our database with stakes in the company increased to 22 from 21 during the third quarter. Samuel Isaly’s Orbimed Advisors reported owning 10.06 million shares of Array Biopharma Inc. (NASDAQ:ARRY) in its 13F for the third quarter. Shares of the company have declined by 21% over the past year.

Follow Jeremy Green's Redmile Group

Disclosure: None

Page 3 of 3